$FBRX News
Last published 2mo ago
- 2mo agoARGXFBRXargenx Completes Acquisition of Forte Biosciences, Inc.GlobeNewswireAcquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx’s immunology pipeline August 27, 2026 – 8:50 AM ET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology
- 3mo agoFBRXSUNSVREXCHMIAre SUNS, VREX, CHMI, FBRX Obtaining Fair Deals for their Shareholders?PR NewswireInsiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.Shareholders are encouraged to
- 3mo agoARGXFBRXargenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.GlobeNewswireAugust 6, 2026 – 7:45 AM ET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology innovation company today announced that Avena Merger Sub Inc. ("Purchaser"), a wholly-owned
- 3mo agoFBRXARGXargenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology PipelineBusiness WireTransaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growth FB102 Phase 1b studies in vitiligo and
- 3mo agoARGXFBRXargenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology PipelineGlobeNewswireTransaction builds on argenx’s prior strategic investment in Forte Biosciences and reflects a disciplined approach to accessing novel biology that can fuel long-term growthFB102 Phase 1b studies in vitiligo and celiac
- 4mo agoFBRXFB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment PeriodBusiness WireStatistically Significant FB102 Benefit Observed By Day 64 and Continued through Week 24 FB102-Treated Subjects Continued Improving Through Week 24 After Completion of the 12-Week Treatment Period Supporting FB102
- 6mo agoFBRXForte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing RulesBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as
- 6mo agoFBRXForte Biosciences, Inc. Announces First Quarter 2026 Results and Provides UpdateBusiness WireFB102 Received Fast Track Designation in Celiac Disease Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases,
- 7mo agoFBRXForte Biosciences Announces Pricing of $150 Million Public OfferingBusiness WireForte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,709,936 shares of its common
- 7mo agoFBRXForte Biosciences Announces Proposed Public OfferingBusiness WireForte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of
- 7mo agoFBRXForte Biosciences, Inc. Announces 2025 Results and Provides UpdateBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its full year 2025 financial results and
- 7mo agoFBRXForte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing RulesBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with
- 8mo agoFBRXForte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing RulesBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with
- 9mo agoFBRXForte Biosciences, Inc. to Present at Upcoming Investor MeetingsBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming
- 10mo agoFBRXForte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing RulesBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with
- 11mo agoFBRXForte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing RulesBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with
- 12mo agoFBRXForte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides UpdateBusiness WireThree clinical trial readouts for FB102 expected in 2026, including phase 2 in celiac disease and phase 1b in both vitiligo and alopecia areata Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a
- 1y agoFBRXForte Biosciences, Inc. to Present at Upcoming Healthcare ConferencesBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, will be presenting at 3 upcoming healthcare
- 1y agoFBRXForte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing RulesBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as
- 1y agoFBRXForte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease SymposiumBusiness WireAdditional data continues to support highly differentiated profile for FB102 in celiac disease Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on
- 1y agoFBRXForte Biosciences, Inc. Announces Results and Provides UpdateBusiness WireThree clinical trial readouts for FB102 expected in 2026, including phase 2 in celiac disease and phase 1b in both vitiligo and alopecia areata Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a
- 1y agoFBRXForte Biosciences Announces Pricing of $75 Million Public OfferingBusiness WireForte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common
- 1y agoFBRXForte Biosciences Announces Proposed Public OfferingBusiness WireForte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of
- 1y agoFBRXForte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B StudyBusiness WirePhase 2 Celiac Disease Trial Initiating with Topline Readout Expected in 2026 Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX),
- 1y agoFBRXForte Biosciences, Inc. Announces Results and Provides UpdateBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2025 financial results and
- 1y agoFBRXForte Biosciences, Inc. Announces Results and Provides Clinical UpdateBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced full year 2024 results and provides a
- 1y agoFBRXForte Biosciences, Inc. to Present at Upcoming Investor MeetingsBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming
- 1y agoFBRXForte Biosciences to Host R&D Day December 3, 2024Business WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will host an R&D Day on December 3,
- 1y agoFBRXForte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune IndicationsBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced an oversubscribed $53 million equity
- 1y agoFBRXForte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business UpdateBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2024 results and provided a
- 2y agoFBRXForte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business UpdateBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced second quarter 2024 results and provided a
- 2y agoFBRXUniversity of Massachusetts et al. vs Forte Biosciences, Inc. - AIA Trial, Final Written DecisionUS Patent Trial and Appeal Board
- 2y agoFBRXForte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing RulesBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as
- 2y agoFBRXForte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business UpdateBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced first quarter 2024 results and provided a
- 2y agoFBRXForte Biosciences, Inc. Announces 2023 Results and Provides Business UpdateBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business
- 2y agoFBRXForte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing RulesBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market
- 2y agoFBRXForte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business UpdateBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2023 results and provided a business
- 3y agoFBRXISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual MeetingBusiness WireBoth Leading Independent Proxy Advisory Firms Conclude Forte's Poor Performance and Dilutive, Anti-Stockholder Actions Under Chairman and CEO Dr. Paul Wagner's Leadership Indicate Boardroom Change is Urgently
- 3y agoFBRXConcerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company's BoardroomBusiness WireExposes Misrepresentations and Distortions Included in Forte's Recent Presentation Encourages Stockholders to Vote for Independent Director Candidates Michael Hacke and Chris McIntyre on the WHITE Proxy Card Ahead of
- 3y agoBCSFBRXMSMICConcerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to StockholdersBusiness WireHighlights Destruction of Nearly 95% in Stockholder Value Under Chairman and CEO Dr. Paul Wagner's Leadership Exposes Forte's Worst-in-Class Governance and Repeated Attempts to Use Corporate Machinery as an
- 3y agoFBRXForte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business UpdateBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-detailed diseases, today announced second quarter 2023 results and provided a business
- 3y agoCABAFBRXJSPRJasper Therapeutics Appoints Scott Brun, M.D., to its Board of DirectorsGlobeNewswireDr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif.,
- 3y agoFBRXForte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing RulesBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market
- 3y agoFBRXForte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business UpdateBusiness WireForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2023 results and provided a business update. First Quarter 2023
- 3y agoALCFBRXINCYJAZZ+3MindMed Sends Letter to Shareholders Highlighting Company's Positive Momentum and Value-Enhancing StrategyBusiness WireFiles Definitive Proxy Materials in Connection with June 15, 2023 Annual Meeting Board's Nominees Possess Essential Pharmaceutical Industry, Capital Allocation and Corporate Governance Experience Needed to Drive
- 3y agoBMYFBRXINCYMNMD+1MindMed Files Preliminary Proxy Statement for 2023 Annual MeetingBusiness WirePresents Highly Qualified Slate of Director Nominees, Including Five Incumbent Board Members and New Independent Candidate David W. Gryska Highlights Significant Positive Momentum to Advance R&D Pipeline and
- 3y agoFBRXForte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business UpdateBusiness Wire-FB-102 Continues to Advance Towards the Clinic Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced full year 2022 results and
- 3y agoFBRXMr. David Gryska Appointed to Forte Biosciences Board of DirectorsBusiness Wire-Addition of Mr. David Gryska Further Strengthens Forte Board of Directors Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), announced today that Mr. David Gryska has been appointed to the Forte Biosciences
- 3y agoFBRXDr. Scott Brun, M.D. Appointed to Forte Biosciences Board of DirectorsBusiness Wire-Forte Leadership is Significantly Strengthened with the Appointment of Dr. Scott Brun, M.D. to the Board of Directors Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), announced today that Dr. Scott Brun,
- 3y agoFBRXForte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business UpdateBusiness Wire-FB-102 Continues to Advance Towards the Clinic and Holds Significant Market Potential Across a Variety of Indications- -Leadership Strengthened with the Appointment of Scott Brun, M.D. to the Board of